Shiroiwa T - Search Results

1

Cost-effectiveness analysis of lifestyle interventions for preventing kidney disease in patients with type 2 diabetes.

Suzuki Y, Hoshi K, Shiroiwa T, Fukuda T. Suzuki Y, et al. Among authors: shiroiwa t. Clin Exp Nephrol. 2023 Sep;27(9):728-736. doi: 10.1007/s10157-023-02357-7. Epub 2023 May 17. Clin Exp Nephrol. 2023. PMID: 37195388

2

[Microdistribution of the lymphatic vessels in the parotid gland].

Shiroiwa T, Amano M, Mori K. Shiroiwa T, et al. Nihon Jibiinkoka Gakkai Kaiho. 1971 Feb;74(2):316-7. Nihon Jibiinkoka Gakkai Kaiho. 1971. PMID: 5106601 Japanese. No abstract available.

3

[The basic researches of Manetol. (2.) Its antigenicity].

SHIROIWA T, HOSEKO S, KAWAMURA K, SAITOM, TAMURA T, TAKAHASHI K. SHIROIWA T, et al. Nihon Jibiinkoka Gakkai Kaiho. 1962 Apr;65:505-19. doi: 10.3950/jibiinkoka.65.505. Nihon Jibiinkoka Gakkai Kaiho. 1962. PMID: 13912116 Japanese. No abstract available.

4

Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery.

Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, Saito M, Iha S, Watanabe T, Katsumata N. Taira N, et al. Among authors: shiroiwa t. Breast Cancer Res Treat. 2011 Aug;128(3):735-47. doi: 10.1007/s10549-011-1631-y. Epub 2011 Jun 17. Breast Cancer Res Treat. 2011. PMID: 21681445 Free article. Clinical Trial.

5

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Shiroiwa T, et al. Breast Cancer Res Treat. 2008 Jun;109(3):559-66. doi: 10.1007/s10549-007-9679-4. Epub 2007 Jul 28. Breast Cancer Res Treat. 2008. PMID: 17661170

6

Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.

Shiroiwa T, Fukuda T, Tsutani K. Shiroiwa T, et al. Clin Ther. 2007 Oct;29(10):2256-67. doi: 10.1016/j.clinthera.2007.10.013. Clin Ther. 2007. PMID: 18042483

7

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. Shiroiwa T, et al. Health Econ. 2010 Apr;19(4):422-37. doi: 10.1002/hec.1481. Health Econ. 2010. PMID: 19382128

8

Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.

Shiroiwa T, Fukuda T, Tsutani K. Shiroiwa T, et al. Br J Cancer. 2009 Jul 7;101(1):12-8. doi: 10.1038/sj.bjc.6605114. Epub 2009 Jun 2. Br J Cancer. 2009. PMID: 19491895 Free PMC article. Clinical Trial.

9

Health utility scores of colorectal cancer based on societal preference in Japan.

Shiroiwa T, Fukuda T, Tsutani K. Shiroiwa T, et al. Qual Life Res. 2009 Oct;18(8):1095-103. doi: 10.1007/s11136-009-9513-z. Epub 2009 Jul 21. Qual Life Res. 2009. PMID: 19626462

10

Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Shiroiwa T, et al. Pharmacoeconomics. 2009;27(7):597-608. doi: 10.2165/11310110-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters